1. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995 Jan;49(1):103-20.
  2. Polak A, Zaug M. Handbook of Experimental Pharmacology vol. 96: Chemotherapy of Fungal Diseases 1990, 504-21.
  3. Zaug M. Amorolfine nail lacquer: once-weekly application in onychomycosis. JAMA South East Asia 1993; 9 Suppl. 4: 19-22
  4. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol. 1992 Sep;17 Suppl 1:26-8.
  5. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003 Sep; 149 Suppl 65:1-4.
  6. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European  Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005 Sep; 19 Suppl 1:8-12.
  7. Monod M. Secreted proteases from dermatophytes. Mycopathologia. 2008 Nov; 166(5):285-94.
  8. Szepietowski JC, Reich A, Garlowska E, Kulig M, Baran  E, for the Onychomycosis Epidemiology Study Group. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses. Arch Dermatol. 2006; Oct; 142:1279-84.
  9. Elewski BE. Onychomycosis : pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415-429.
  10. Hay RJ, Baron R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011 Dec; 65(6):1219-27
  11. Tosti A, Arenas-Guzmán R. Patients at risk of onychomycosis-risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005 Sept;19(S1):13-6.
  12. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat. 2008 Jan; 19(2):72-81.
  13. Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association  of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58
  14. Polak A. Amorolfine: A review of its mode of action and in vitro and in vivo antifungal activity. Suppl to J Am Acad Dermatol South-East Asia. 1993 July:11-18.
  15. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dec; 15(6):489-502.
  16. Polak A, Jäckel A, Noack A, Kappe R.Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives. Mycoses. 2004 Jun; 47(5-6):184-92.
  17. Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010; 24(4):420-3.